Date: 2014-10-20
Type of information: Grant
Company: Immupharma (UK)
Investors: region of Aquitaine (France)
Amount: €400,000
Funding type: grant
Planned used: The grant will be used to develop Ureka\'s Urelix technology. The Urelix technology is a way to mimic natural peptides having a helical conformation with artificial residues in order to strengthen this conformation and protect it from enzymatic degradation. ImmuPharma announced recently that one of the first targets for the Urelix technology is GLP-1, a key peptide in diabetes. This grant confirms the key role Ureka is playing in the biotechnology landscape of the Bordeaux region through its collaboration with ImmuPharma\'s longstanding and successful research partner, Centre Nationale de la Recherche Scientifique \"CNRS\" and Bordeaux University\'s research team incubator, Institut Europeen de Chimie et Biologie, as well as the credibility of its technologies.
Others: * On October 20, 2014, ImmuPharma, the specialist drug discovery and development company, has announced that the French region of Aquitaine (around Bordeaux) has awarded ImmuPharma\'s subsidiary Ureka a non-refundable grant of approx. €400,000 to develop Ureka\'s Urelix technology.
Therapeutic area:
